https://www.selleckchem.com/pr....oducts/nedometinib.h
Mycobacterium abscessus is increasingly recognized as an emerging opportunistic pathogen causing severe lung diseases. As it is intrinsically resistant to most conventional antibiotics, there is an unmet medical need for effective treatments. Repurposing of clinically validated pharmaceuticals represents an attractive option for the development of chemotherapeutic alternatives against M. abscessus infections. In this context, rifabutin (RF has been shown to be active against M. abscessus and has raised renewed interest in using ri
Like
Comment
Share
